Abstract: ObjectiveTo study the effect of percutaneous vertebroplasty combined with postural reduction in the treatment of thoracolumbar compression fractures in the elderly.MethodsFrom February 2014 to February 2017, a total of 150 elderly patients with thoracolumbar compression fractures treated in our hospital were selected as the research object, and were randomly divided into two groups, with 75 cases in each. The observation group was treated with percutaneous vertebroplasty (PVP), and the control group was treated with percutaneous kyphoplasty (PKP).ResultsThe total effective rate of the observation group was 94.67%, and the control group was 96%. There was no significant difference in the total effective rate between the groups (P>0.05). There was no significant difference of the postoperative Cobb angle between the two groups (P>0.05). But the compression rate of the anterior and posterior edge of the vertebral body of the observation group was significantly higher than that of the control group (P<0.05). After treatments, the Oswestry dysfunction index and VAS score decreased significantly in each group. But there was no significant difference of the Oswestry dysfunction index and VAS score between these two groups (P>0.05).ConclusionPVP and PKP are both reliable in pain relief and life quality improvement for the thoracolumbar compression fractures patients in the elderly. But it has obvious advantages of the restore of the compressed vertebral body in PKP. While it can achieve wider indications, more simple procedures and relative lower costs of PVP.
崔志刚，张德光，刘福全. 经皮穿刺椎体成形术结合体位复位在老年胸腰椎压缩性骨折中的应用效果[J]. 中国现代手术学杂志, 2017, 21(5): 382-386.
CUI Zhigang, ZHANG Deguang, LIU Fuquan. Application of Percutaneous Vertebroplasty Combined with Postural Reduction in the Treatment of Thoracolumbar Compression Fractures in the Elderly. Chinese Journal of Modern Operative Surgery, 2017, 21(5): 382-386.
Scheiner S, Pivonka P, Smith DW, et al. Mathematical modeling of postmenopausal osteoporosis and its treatment by the anticatabolicdrug denosumab［J］. Int J Numer Method Biomed Eng, 2014,30(1):127. doi: 10.1002/cnm.2584.
Kanis JA, McCloskey EV, Johansson H, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausalwomen［J］. Osteoporos Int,2013,24(1):2357. doi: 10.1007/s001980122074y.
［8］
Cosman F, de Beur SJ, LeBoff MS, et al. Clinician's guide to prevention and treatment of osteoporosis［J］. Osteoporos Int, 2014,25(10):23592381. doi: 10.1007/s0019801427942.
Adler RA, ElHajj Fuleihan G, Bauer DC, et al. Managing Osteoporosis in Patients on LongTerm Bisphosphonate Treatment: Report of a TaskForce of the American Society for Bone and Mineral Research［J］. J Bone Miner Res, 2016,31(1):1635. doi: 10.1002/jbmr.2708.
［11］
Nayak S, Edwards DL, Saleh AA, et al. Systematic review and metaanalysis of the performance of clinical risk assessment instruments for screening for osteoporosis or low bone density［J］. Osteoporos Int, 2015,26(5):15431554. doi: 10.1007/s0019801530251.
Hadji P, Papaioannou N, Gielen E, et al. Persistence, adherence, and medicationtaking behavior in women with postmenopausalosteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12month results from a European noninterventional study［J］. Osteoporos Int, 2015 ,26(10):24792489. doi: 10.1007/s0019801531644.
2017, Vol. 21 
